Back to top
more

NeoGenomics (NEO)

(Real Time Quote from BATS)

$15.29 USD

15.29
193,563

-0.50 (-3.17%)

Updated Nov 15, 2024 01:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Earnings Preview: NeoGenomics (NEO) Q4 Earnings Expected to Decline

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Surpasses Q3 Earnings Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 500.00% and -2.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Looks Good: Stock Adds 5.5% in Session

NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ANIK vs. NEO: Which Stock Is the Better Value Option?

ANIK vs. NEO: Which Stock Is the Better Value Option?

NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 55.56% and 1.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to Decline

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Reports Q1 Loss, Misses Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of -200.00% and -0.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Tops Q4 Earnings and Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 42.86% and 2.31%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

Healthcare ETF (IHF) Tops in October: 5 Best Stocks

Inside the best performing stocks of the top ETF of October.

NeoGenomics (NEO) Tops Q3 Earnings and Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 16.67% and 5.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Meets Q2 Earnings Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and 5.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Earnings Expected to Grow: Should You Buy?

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Hits Fresh High: Is There Still Room to Run?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NeoGenomics (NEO) Tops Q1 Earnings and Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 40.00% and 9.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: Ready Capital, Gladstone, NeoGenomics, Digi and Paramount

Zacks.com featured highlights include: Ready Capital, Gladstone, NeoGenomics, Digi and Paramount

NeoGenomics (NEO) Reports Next Week: What to Know Ahead of the Release

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Swarup Gupta headshot

5 Breakout Stocks for Stellar Returns

This method involves zeroing in on stocks whose prices vary within a narrow band.